title: Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles.
abstract: OBJECTIVE
  Mannosylation of vaccines is a promising strategy to selectively target vaccine antigens to the mannose receptor expressed on dendritic cells (DCs). The purpose of this study was to investigate the effect of mannan (MN) chemically conjugated to poly(D, L-lactide-co-glycolic acid) (PLGA) nanoparticles (NPs) on antigen-specific T-cell responses elicited by a model antigen (ovalbumin, OVA) loaded in PLGA-NPs.
  
  
  METHODS
  In vitro T-cell proliferation assay was done to assess the ability of DCs treated with OVA-NPs (±MN decoration) to induce antigen-specific T-cell activation. The efficacy of this vaccination strategy was further evaluated in vivo, where T-cell proliferation was performed to evaluate activation of T-cell responses in lymph nodes and spleens isolated from the vaccinated mice.
  
  
  RESULTS
  Our results demonstrate that MN-decorated antigen-loaded PLGA-NPs simultaneously enhanced antigen-specific CD4+ and CD8+ T-cell responses compared to non-decorated NPs.
  
  
  CONCLUSIONS
  MN decoration of PLGA-NPs is a promising strategy for enhancing antigen-specific T-cell responses.
authors.affiliation: Faculty of Pharmacy and Pharmaceutical Sciences 3133 Dentistry/Pharmacy Centre, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Samar
authors.initials: S
authors.lastname: Hamdy
authors.forename: Azita
authors.initials: A
authors.lastname: Haddadi
authors.forename: Anooshirvan
authors.initials: A
authors.lastname: Shayeganpour
authors.forename: John
authors.initials: J
authors.lastname: Samuel
authors.forename: Afsaneh
authors.initials: A
authors.lastname: Lavasanifar
mesh_terms: D000818:Animals; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D003713:Dendritic Cells / Q000276:immunology; D004337:Drug Carriers / Q000737:chemistry*; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D019344:Lactic Acid / Q000737:chemistry*; D037181:Lectins, C-Type / Q000276:immunology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008351:Mannans / Q000737:chemistry*; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011956:Receptors, Cell Surface / Q000276:immunology; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000941:Antigens; D004337:Drug Carriers; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D037181:Lectins, C-Type; D008351:Mannans; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D011956:Receptors, Cell Surface; D014612:Vaccines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D010047:Ovalbumin